Lupin 2024

Aurobindo receives FDA approval for prednisone tablets

Print Friendly, PDF & Email

EAST WINDSOR, N.J. — Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application prednisone tablets USP, 1mg. Aurobindo Pharma’s prednisone tablets USP, 1mg, are an AB-rated generic equivalent to the reference listed drug (RLD), Meticorten Tablets, of Schering Corp Sub Schering Plough Corp.

Prednisone tablets are indicated in the following conditions:

• Endocrine Disorders

• Rheumatic Disorders

• Collagen Diseases

• Dermatologic Diseases

• Allergic States

• Ophthalmic Diseases

• Respiratory Diseases

• Hematologic Disorders

• Neoplastic Diseases

• Edematous States

• Gastrointestinal Diseases

• Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.


Comments are closed.